The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with a public offering by Recursion Pharmaceuticals, Inc. of 35,384,614 shares of Class A common stock for total gross proceeds of approximately $230 million. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.”

Recursion Pharmaceuticals is a leading clinical stage biotechnology company decoding biology to industrialize drug discovery. Recursion is headquartered in Salt Lake City, Utah.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Matthew Franklin. Partner Frank J. Azzopardi and associates Adrian Rabin and Ted Talas provided intellectual property advice. Partner Mario J. Verdolini and associate Alanna Phillips provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post